Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model

Background Access to providers and programs that provide medications for opioid use disorder (MOUD) remains a systemic barrier for patients with opioid use disorder (OUD), particularly if they live in rural areas. The Rural Access to Medication Assisted Treatment (MAT) in Pennsylvania Project (Project RAMP) addressed this problem with a multisystem partnership that recruited, trained, and supported rural primary care providers to provide MOUD and implement an integrated care model (ICM) for patients with OUD. Given the demonstrated efficacy of Project RAMP, this article summarizes our recruitment strategies, including feasibility concerns for further expansion into other regions. Methods The approach for recruiting implementation sites included two phases: partner outreach and site identification. Once recruited, the Systems Transformation Framework guided planning and implementation activities. Recruitment and implementation activities were assessed with implementation trackers and evaluated by providers via key informant interviews (KIIs). Results Project RAMP recruited 26 primary care practices from 13 counties, including nine health systems and two private practice groups—exceeding the original target of 24 sites. There was a median of 49 days from first contact to project onboarding. A total of 108 primary care practices spanning 22 health systems declined participation. Findings from the KIIs highlighted the value of engaging PCPs by connecting to a shared vision (i.e., improving the quality of patient care) as well as addressing perceived participation barriers (e.g., offering concierge technical assistance to address lack of training or resources). Conclusion Findings highlight how successful recruitment activities should leverage the support of health system leadership. Findings also emphasize that aiding recruitment and engagement efforts successfully addressed prescribers’ perceived barriers to providing MOUD as well as facilitating better communication among administrators, PCPs, behavioral health professionals, care managers, and patients. Plain Language Summary: Opioid use disorder (OUD) is one of the leading causes of preventable illness and death. The standard of care for OUD is the provision of medications for opioid use disorder (MOUD) and the application of an integrative integrated care model (ICM) where behavioral health is blended with specialized medical services. Unfortunately, access to providers and healthcare facilities that provide MOUD or apply an ICM remains a systemic barrier for patients with OUD, particularly if they live in rural areas. Although there is no one-size-fits-all approach to implementing MOUD in primary care, findings from Project The Rural Access to Medication Assisted Treatment (MAT) in Pennsylvania Project (Project RAMP) highlight strategies that may improve future MOUD and ICM implementation efforts in similar rural contexts. Specifically, future efforts to increase MOUD capacity by recruiting new providers should be prepared to leverage health system leadership, address provider barriers via training and expert consultation, and facilitate connections to local behavioral health providers. This approach may be helpful to others recruiting health systems and primary care practices to implement new care models to use MOUD in treating patients with OUD.

[1]  Nate C. Apathy,et al.  Evaluation of electronic recruitment efforts of primary care providers as research subjects during the COVID-19 pandemic , 2022, BMC Primary Care.

[2]  D. Jonas,et al.  Barriers to recruiting primary care practices for implementation research during COVID-19: A qualitative study of practice coaches from the Stop Unhealthy (STUN) Alcohol Use Now trial , 2022, Implementation research and practice.

[3]  Nora C. Bridges,et al.  Medications for Opioid Use Disorder in Rural Primary Care Practices: Patient and Provider Experiences , 2022, SSRN Electronic Journal.

[4]  K. Zivin,et al.  Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. , 2021, JAMA.

[5]  Sally A. Kraft,et al.  Multidisciplinary Treatment of Opioid Use Disorder in Primary Care Using the Collaborative Care Model , 2021, Substance abuse.

[6]  D. Kelley,et al.  Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder , 2021, Journal of addiction medicine.

[7]  P. Nourjah,et al.  “One size does not fit all” and other lessons learned from grants for implementation of the AHRQ medication assisted treatment for opioid use disorder in rural primary care , 2021, Substance abuse.

[8]  J. Westfall,et al.  The who, the what, and the how: A description of strategies and lessons learned to expand access to medications for opioid use disorder in rural America , 2021, Substance abuse.

[9]  James H. Ford,et al.  Improving medication access within integrated treatment for individuals with co-occurring disorders in substance use treatment agencies , 2021, Implementation research and practice.

[10]  Kayne D. Mettert,et al.  Transitioning patients from outpatient mental health services to primary care: A rapid literature review , 2021, Implementation research and practice.

[11]  Cheri J. Shapiro,et al.  Provider self-efficacy in delivering evidence-based psychosocial interventions: A scoping review , 2021, Implementation research and practice.

[12]  M. Farkas,et al.  Ready to roll: Strategies and actions to enhance organizational readiness for implementation in community mental health , 2021, Implementation research and practice.

[13]  Kayne D. Mettert,et al.  Determining the influence of intervention characteristics on implementation success requires reliable and valid measures: Results from a systematic review , 2021, Implementation research and practice.

[14]  Audrey L. Jones,et al.  Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities , 2020, The American journal of drug and alcohol abuse.

[15]  A. Dopp,et al.  Combatting the Stigma of Addiction - The Need for a Comprehensive Health System Approach. , 2020, NAM perspectives.

[16]  Christopher M. Jones,et al.  The American Opioid Epidemic in Special Populations: Five Examples. , 2020, NAM perspectives.

[17]  E. Hawkins,et al.  Article Commentary: Stepped Care for Opioid Use Disorder Train the Trainer (Scoutt) Initiative: Expanding Access to Medication Treatment for Opioid Use Disorder within Veterans Health Administration Facilities , 2020, Substance abuse.

[18]  B. Madras,et al.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. , 2020, NAM perspectives.

[19]  T. Wiegand,et al.  The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. , 2020, Journal of addiction medicine.

[20]  David K. Wyant,et al.  Compositional and contextual factors associated with drug overdose deaths in the United States , 2020, Journal of addictive diseases.

[21]  Julie A. Jackson,et al.  Understanding Barriers and Facilitators to the Uptake of Best Practices for the Treatment of Co-Occurring Chronic Pain and Opioid Use Disorder , 2019, Journal of dual diagnosis.

[22]  Robin Ghertner U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. , 2019, Drug and alcohol dependence.

[23]  M. Schechter,et al.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review , 2019, Substance Abuse Treatment, Prevention, and Policy.

[24]  S. Friedman,et al.  Social norms associated with nonmedical opioid use in rural communities: a systematic review. , 2019, Translational behavioral medicine.

[25]  K. Peterson,et al.  Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder , 2019 .

[26]  D. Kelley,et al.  Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers , 2019, Addiction Science & Clinical Practice.

[27]  Christopher M. Jones,et al.  Co-occurring substance use and mental disorders among adults with opioid use disorder. , 2019, Drug and alcohol dependence.

[28]  R. Rahman,et al.  Nurturing Practitioner-Researcher Partnerships to Improve Adoption and Delivery of Research-Based Social and Public Health Services Worldwide , 2019, International journal of environmental research and public health.

[29]  S. Weiner,et al.  Stewarding Recovery from the Opioid Crisis Through Health System Initiatives , 2019, The western journal of emergency medicine.

[30]  R. Kullar,et al.  The association between perceived stigma and substance use disorder treatment outcomes: a review , 2018, Substance abuse and rehabilitation.

[31]  A. Leshner,et al.  Medications for Opioid Use Disorder Save Lives , 2019 .

[32]  D. Patterson,et al.  Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine. , 2018, American journal of preventive medicine.

[33]  A. Bohnert,et al.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. , 2018, American journal of preventive medicine.

[34]  Mindy E. Flanagan,et al.  Inside help: An integrative review of champions in healthcare-related implementation , 2018, SAGE open medicine.

[35]  Benjamin P Linas,et al.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.

[36]  Kathy A Scott,et al.  The Power of the Frame: Systems Transformation Framework for Health Care Leaders , 2018, Nursing administration quarterly.

[37]  Christopher M. Jones,et al.  Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. , 2015, JAMA.

[38]  L. A. Kazal,et al.  Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. , 2015, Rural and remote health.

[39]  E. Brouwers,et al.  [Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review]. , 2015, Tijdschrift voor psychiatrie.

[40]  Thomas R Frieden,et al.  Medication-assisted therapies--tackling the opioid-overdose epidemic. , 2014, The New England journal of medicine.

[41]  R. Rosenblatt,et al.  Barriers to Primary Care Physicians Prescribing Buprenorphine , 2014, The Annals of Family Medicine.

[42]  Udi E. Ghitza,et al.  Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group , 2013, Public Health Reviews.

[43]  P. Skorga,et al.  Collaborative care for depression and anxiety problems , 2013 .

[44]  Sandra E. Larios,et al.  Confidentiality protections versus collaborative care in the treatment of substance use disorders , 2013, Addiction Science & Clinical Practice.

[45]  Mark T Hegel,et al.  Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. , 2002, JAMA.

[46]  A T McLellan,et al.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.

[47]  J. Wall Collaborative Care. , 1993, Virginia dental journal.

[48]  Daniel Roos,et al.  The machine that changed the world : the story of lean production , 1991 .

[49]  元木 良一,et al.  Drug Overdose , 1972, Southern medical journal.